Valuation: Forte Biosciences, Inc.

Market Cap 109.94Cr 96Cr 89Cr 82Cr 154.02Cr 11TCr 157.44Cr 1.06TCr 416.78Cr 5.19TCr 412.86Cr 403.81Cr 18TCr P/E 2026 *
-11x
P/E 2027 * -10.6x
Enterprise Value 109.94Cr 96Cr 89Cr 82Cr 154.02Cr 11TCr 157.44Cr 1.06TCr 416.78Cr 5.19TCr 412.86Cr 403.81Cr 18TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+8.60%
1 week+11.25%
Current month+129.93%
1 month+177.77%
3 months+44.04%
6 months+60.67%
Current year+79.17%
1 week 40.11
Extreme 40.11
50
1 month 16.89
Extreme 16.89
50
Current year 15.51
Extreme 15.51
50
1 year 9.1
Extreme 9.1
50
3 years 4.11
Extreme 4.11
50
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

Chief Executive Officer

2,598 0.0127%
01/07/26 Fiscal year

Chief Financial Officer

884 0.0043%
16/06/26 Free

Chief Financial Officer

22,000 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
+8.60%+11.25%+390.56%+95.73% 109.94Cr
-7.17%-2.63%+49.59%+74.24% 5.6TCr
+0.24%-5.62%+54.73%+125.15% 5.37TCr
+0.80%-6.31%+3.98%+423.29% 2.33TCr
-0.09%-0.01%-17.62%-14.67% 2.32TCr
-5.95%-0.22%+35.96%-9.58% 2.06TCr
-1.14%-3.16%+32.88%-28.80% 1.78TCr
-5.16%-7.00%+177.56%+326.39% 1.61TCr
-6.91%+2.40%+36.86%+636.97% 1.59TCr
+0.43%-1.03%+24.63%+191.40% 1.4TCr
Average -1.61%+1.13%+78.91%+182.01% 2.42TCr
Weighted average by Cap. -2.85%-2.09%+45.29%+156.76%

Financials

2026 *2027 *
Net sales - -
Net income -9.55Cr -8.35Cr -7.7Cr -7.1Cr -13Cr -920.05Cr -14Cr -92Cr -36Cr -450.6Cr -36Cr -35Cr -1.55TCr -13Cr -11Cr -11Cr -9.7Cr -18Cr -1.26TCr -19Cr -125.72Cr -49Cr -615.19Cr -49Cr -48Cr -2.12TCr
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
18/26/18 $48.86 +8.60% 5,95,671
16/26/16 $44.99 +1.90% 7,86,156
15/26/15 $44.15 +2.20% 6,31,370
14/26/14 $43.20 -2.09% 6,78,955
13/26/13 $44.12 +0.46% 7,42,886
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
44.99USD
Average target price
64.75USD
Spread / Average Target
+43.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock